Compare Etsy Inc (ETSY) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs GSK plc — how do they compare? Etsy Inc trades at $76.71 (market cap $6.90B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 13.3× Etsy Inc's market cap, and GSK plc pays a 3.9% dividend while Etsy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and GSK plc for 93 Days on average.
| ETSY | GSK | |
|---|---|---|
Market Cap | $6.90B | $91.88B |
Volume | 2,923,867 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $61.18 |
52-Week Low | $44.05 | $43.24 |
Typical Hold Time | 67 Days | 93 Days |
Enterprise Value | $8.85B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $75.14, up 5.11% today, showing strong momentum with three consecutive earnings beats. The stock maintains a bullish technical outlook with support at $73 and resistance at $76. Fundamentally, revenue growth has been steady at $2.9B annually, though net margins compressed to 5.65% in 2025. Recent news highlights AI integration and payment partnerships as growth catalysts.
The outlook remains positive with a $85.94 analyst price target suggesting 14% upside. Key risks include high debt levels and competitive pressures. Wall Street sentiment is bullish (53% buy ratings), but investors should monitor margin trends and execution of AI initiatives for sustained growth.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
